Investigating Rift Valley Fever Virus and Emerging Infectious Diseases in East and Central Africa
Surveillance and Transmission Studies in Humans and Animals
Led by Washington State University · Updated on 2026-10-05
5000
Participants Needed
10
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Rift Valley fever RVF is a disease transmitted from livestock to humans, commonly occurring in East and Central Africa where major epidemics have been reported over the past 50 years. Researchers are investigating the burden of RVF and other infectious diseases in hotspots across Kenya, Uganda, Tanzania, and the Democratic Republic of Congo during periods between outbreaks. This study aims to understand how the virus circulates among humans, wildlife, and livestock to support early warning and prevention strategies.
The study includes multiple approaches such as hospital-based surveillance of patients with acute fever, community surveys of livestock and humans, sampling at slaughter houses, wildlife sampling, and mosquito vector studies. These efforts span several years and involve testing blood and tissue samples for RVF virus and other pathogens using molecular and serological techniques. Modeling studies will further analyze ecological and climatic factors affecting virus transmission.
Participants will be involved in providing blood samples, answering questionnaires about animal contact and behaviors, and may be followed for up to two years after enrollment. Researchers will monitor virus exposure, identify risk factors, and evaluate disease presence using laboratory tests and surveys. The study also includes analysis of archived samples and ongoing monitoring of mosquito populations to better understand and predict RVF outbreaks in the region.
CONDITIONS
Brief Title
RVF and Other Emerging Infectious Diseases in East and Central Africa
Research Team
J
Jeanette A Dawa, PhD
M
M. Kariuki Njenga, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborating Sponsor
Who Can Participate
Age: 2Years +
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
Persons 10 years of age or older with undifferentiated acute fever (temperature ≥ 37.5°C) or reported fever in the past 4 weeks who test malaria negative
Persons 10 years of age or older with undifferentiated acute fever (temperature ≥ 37.5°C) or reported fever in the past 4 weeks who test malaria positive
Persons 10 years of age or older with unexplained bleeding from various sites or infectious illness of unknown cause requiring hospitalization
Members of households aged 2 years or older for community cross-sectional study
You will not qualify if you...
Individuals who do not consent or refuse written consent
Participants who are severely ill without a next of kin to provide consent or witness
Known blood clotting disorders
Allergies related to injections
History of fainting during previous injections or blood collection
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Health Facility Cohort Study
Duration - Up to 24 months
Participants with acute or recent fever are enrolled at health facilities and followed for up to 24 months, providing blood samples and clinical information.
Multiple visits during follow-up
Community Cross-Sectional Surveys
Duration - 5 years
Household members are sampled in 2 to 6 surveys over 5 years to collect blood samples and information about animal contact and behaviors.
2 to 6 surveys primarily during rainy seasons
Animal and Vector Sampling
Duration - Ongoing throughout study period
Sampling of livestock, wildlife, and mosquitoes is conducted to detect virus presence and study vector behavior and ecology.
Sampling during community surveys and targeted trapping
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Phase 2 Study of Safety and Immune Response to Rift Valley Fever Vaccine TSI-GSD 200 in Adults at Risk of Exposure
Assessing the Spread of Multiple Infectious Diseases in Cambodia Using a One Health Approach
Including Children and Adults Ages 2 to 75 Years
A Nationwide Study to Guide Public Health Actions
Investigating Rift Valley Fever Virus and Emerging Infectious Diseases in East and Central Africa
Surveillance and Transmission Studies in Humans and Animals
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Technical validation and implementation of a multiplex real-time PCR for differential diagnostic detection of Zika virus, yellow fever virus, dengue virus and chikungunya virus (ZYDC-PCR).
Anne Hauner, Ana Julia Benítez, Noella Mulopo-Mukanya...